COMP <GO>
ZJYL vs AVR // REVENUE GROWTH (YOY)
JIN MEDICAL INTERNATIONAL LTD. (Class A) (NASDAQ) VS. Anteris Technologies Global Corp. (NASDAQ) • 15-METRIC TALLY: ZJYL 6
— AVR 2
▲ REVENUE GROWTH (YOY) LEADER: ZJYL
LAST: $1.86 (-2.10%) • MKT CAP: $294.2M
revenue-growth
-12.00%
LAST: $6.42 (+5.25%) • MKT CAP: $625.9M
revenue-growth
-29.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZJYL VS. AVR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ZJYL | AVR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 29.20% | 70.30% | -41.10 | AVR | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | 47.1x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.27% | -12.74% | +11.47 | ZJYL | /fcf-yield <GO> |
| Operating Margin | 2.90% | -60.00% | +62.90 | ZJYL | /operating-margins <GO> |
| Net Profit Margin | 5.80% | -60.00% | +65.80 | ZJYL | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | -12.00% | -29.20% | +17.20 | ZJYL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 2/9 | +2.00 | ZJYL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.3 | 44.1 | +0.20 | ZJYL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $294.2M | $625.9M | -$331.7M | AVR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ZJYL REV | AVR REV | ZJYL GROSS % | AVR GROSS % | ZJYL FCF | AVR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $20.7M | $1.9M | 29.2% | 70.3% | -$3.7M | -$79.8M |
| FY 2024 | $23.5M | $2.7M | 40.4% | 46.8% | -$1.4M | -$63.5M |
| FY 2023 | $19.8M | — | — | — | $3.1M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZJYL // BETA —
AVR // BETA —